Stem Cell Reviews and Reports

, Volume 13, Issue 2, pp 192–197

Stem Cell Recipes of Bone Marrow and Fish: Just What the Stroke Doctors Ordered



Stem cell therapy for stroke has advanced from the laboratory to the clinic, but remains as an experimental treatment. Two lines of transplant regimens have emerged, namely the “early bird” peripheral injections in subacute stroke patients and the “late night” direct intracerebral treatments in chronic stroke patients. Autologous bone marrow-derived stem cells, which only required minimal manipulations during graft cell preparation, gained fast-track entry into the clinic, while gene modified stem cells necessitated overcoming more stringent regulatory criteria before they were approved for clinical use. Safety of the stem cell therapy can be declared from these clinical trials, but efficacy warrants further investigations. Here, we offer insights into the translation of cell therapy from the laboratory to the clinic, in the hopes that highlighting the lessons we learned from this experience will guide the optimization of functional outcomes of future clinical trials of stem cell therapy for stroke.


Ischemic stroke Stem cell therapy Clinical trials Translational research 

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  1. 1.Department of Molecular BiosciencesUniversity of California DavisDavisUSA
  2. 2.Center of Excellence for Aging & Brain Repair, Department of Neurosurgery and Brain RepairUniversity of South Florida College of MedicineTampaUSA

Personalised recommendations